HASHEM EL-SERAG to Biomarkers, Tumor
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Biomarkers, Tumor.
Connection Strength
2.206
-
HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2026 Mar; 84(3):578-586.
Score: 0.516
-
HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States. Hepatology. 2025 Feb 01; 81(2):465-475.
Score: 0.471
-
Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008 Feb 15; 167(4):377-89.
Score: 0.150
-
Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatol Commun. 2026 Aug 01; 10(8).
Score: 0.136
-
Validation of longitudinal biomarker screening algorithms for HCC detection in patients with cirrhosis. Hepatol Commun. 2026 Mar 01; 10(3).
Score: 0.132
-
Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 03; 168(3):556-567.e7.
Score: 0.121
-
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
Score: 0.100
-
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022 03; 75(3):541-549.
Score: 0.099
-
A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila). 2021 06; 14(6):667-674.
Score: 0.094
-
A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women. Cancer Prev Res (Phila). 2019 04; 12(4):237-246.
Score: 0.081
-
A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women. Cancer Med. 2018 05; 7(5):2180-2191.
Score: 0.076
-
Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol. 2013 Aug; 7(6):493-5.
Score: 0.055
-
Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47.
Score: 0.055
-
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology. 2010 Jul; 52(1):132-41.
Score: 0.045
-
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2009 Jun; 55(2):123-38.
Score: 0.042
-
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. Int J Cancer. 2026 Mar 01; 158(5):1193-1203.
Score: 0.032